🔍

Kimia Biosciences Ltd (530313)

📊 BSE: 530313 🏢 Pharmaceuticals 📢 Latest filing: 10 Aug 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q4 FY26)

In its latest reported quarter, Q4 FY26, Kimia Biosciences' revenue was ₹27.2 Cr (-28.9% year on year, -9.6% on the previous quarter), and net profit ₹0.4 Cr (-81.4% year on year); the operating margin was 9.8%.

Q4 FY26 (₹ Cr)	Value	YoY vs Q4 FY25	QoQ
Revenue	₹27.2	-28.9%	-9.6%
Operating profit	₹2.7	-67.5%	-59.5%
Net profit	₹0.4	-81.4%	-93.2%
EPS (₹)	0.08	-81.0%	-93.0%
Operating margin	9.8%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Kimia Biosciences Q1 Revenue Drops 12% YoY to ₹20.72 Cr; Reports Comprehensive Loss

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 10 Aug 2026, 05:12 PM

Kimia Biosciences reported a weak performance for Q1 FY27, with revenue from operations declining 12.1% YoY to ₹20.72 Cr. While the company posted a marginal Net Profit of ₹0.36 Cr, it recorded a Total Comprehensive Loss of ₹0.11 Cr due to negative adjustments in other comprehensive income. Sequentially, revenue saw a sharp contraction of 23.8% compared to the March 2026 quarter. The company continues to operate with high leverage, evidenced by a debt-to-equity ratio of 1.94.

Revenue from operations fell 12.1% YoY to ₹20.72 Cr from ₹23.58 Cr in the previous year's corresponding quarter.
Net Profit for the quarter stood at ₹0.36 Cr, down 17% from ₹0.43 Cr in Q1 FY26.
Total Comprehensive Income turned negative at -₹0.11 Cr due to a ₹0.46 Cr loss in remeasurement of defined benefit plans.
Cost of materials consumed remained high at ₹16.57 Cr, representing 80% of revenue from operations.
Earnings Per Share (EPS) for the quarter was ₹0.08, compared to ₹0.13 in the year-ago period.

💡 Investors should monitor the company's ability to stabilize its top-line growth and manage its high debt-to-equity ratio of 1.94, which poses a risk in a high-interest-rate environment.

Rs 20.72 Cr Revenue in Q1 FY27; Net Profit Declines 17% YoY

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 10 Aug 2026, 04:52 PM

Kimia Biosciences reported a weak start to FY27, with Q1 revenue declining 12.1% YoY to Rs 20.72 Cr compared to Rs 23.58 Cr in Q1 FY26. Net profit for the quarter stood at Rs 0.36 Cr, a 17% decrease from Rs 0.43 Cr in the same period last year. Sequentially, the performance was even more subdued, with revenue dropping 23.8% from Rs 27.20 Cr in Q4 FY26. The company maintains a high debt-to-equity ratio of 1.94, making the top-line contraction a point of concern for debt servicing.

Revenue from operations decreased to Rs 20.72 Cr, down 12.1% from Rs 23.58 Cr in the year-ago quarter.
Net profit for Q1 FY27 was Rs 0.36 Cr, compared to Rs 0.43 Cr in Q1 FY26.
Total expenses were reduced to Rs 20.31 Cr from Rs 23.74 Cr YoY, primarily due to lower material costs.
Finance costs remained relatively stable at Rs 0.83 Cr, accounting for 4% of total revenue.
Earnings Per Share (EPS) for the quarter remained flat at Rs 0.08 compared to the immediate previous quarter.

💡 Investors should monitor the company's ability to stabilize its top-line growth and improve operating margins, which are currently under pressure. The high debt-to-equity ratio (1.94) requires close attention to interest coverage in future quarters.

Kimia Biosciences to consider Q1 FY27 results on August 10, 2026

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 03 Aug 2026, 03:58 PM

Kimia Biosciences has scheduled a board meeting for August 10, 2026, to approve standalone unaudited financial results for the quarter ended June 30, 2026. The company currently has a market capitalization of Rs 150 Cr and reported TTM revenue of Rs 115 Cr. The trading window for insiders has been closed since July 1, 2026, and will reopen 48 hours after the results are declared. This is a routine regulatory filing required under SEBI (LODR) Regulations.

Board meeting scheduled for August 10, 2026, to approve Q1 FY27 results.
Trading window for designated persons closed from July 1, 2026.
Company reported a TTM PAT of Rs 7 Cr against a TTM revenue of Rs 115 Cr.
Promoter holding remains stable at 74.94% as of March 2026.

💡 Monitor the financial results on August 10 to assess if the company can improve its operating profit margin (12.4%) and manage its high debt-to-equity ratio of 1.94.

Kimia Biosciences Appoints New Cost, Internal, and Secretarial Auditors for FY27

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 01 Aug 2026, 11:17 PM

Kimia Biosciences has announced a comprehensive update to its audit panel following a board meeting on August 1, 2026. The company appointed M/s Mahesh Singh & Co. as Cost Auditor and M/s Chaudhry & Associates as Internal Auditor for FY 2026-27. Additionally, the company discontinued the services of its previous Secretarial Auditor, M/s M & Co., and appointed M/s Maya Sharma and Associates for both FY 2025-26 and FY 2026-27. These changes are largely procedural for a company of this size (Market Cap: ₹146 Cr).

Appointment of M/s Mahesh Singh & Co. as Cost Auditor for the Financial Year 2026-27
Appointment of M/s Chaudhry & Associates as Internal Auditor for the Financial Year 2026-27
Discontinuance of M/s M & Co. as Secretarial Auditor effective August 1, 2026
Appointment of M/s Maya Sharma and Associates as Secretarial Auditor for FY 2025-26 and FY 2026-27
Board meeting conducted and concluded within 30 minutes (4:00 PM to 4:30 PM)

💡 Investors should monitor the next annual report for any specific observations or qualifications from the new auditors, particularly the secretarial auditor covering the previous fiscal year.

Kimia Biosciences Appoints New Cost, Internal, and Secretarial Auditors for FY27

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Aug 2026, 11:13 PM

Kimia Biosciences has announced a refresh of its audit panel following a board meeting on August 1, 2026. The company appointed M/s Mahesh Singh & Co. as Cost Auditor and M/s Chaudhry & Associates as Internal Auditor for FY 2026-27. Additionally, M/s Maya Sharma and Associates has been appointed as the Secretarial Auditor for both FY 2025-26 and FY 2026-27, replacing M/s M & Co. These appointments are standard regulatory requirements for a company with a TTM revenue of Rs 115 Cr.

Appointment of M/s Mahesh Singh & Co. as Cost Auditor for FY 2026-27, bringing over 25 years of experience.
Appointment of M/s Chaudhry & Associates as Internal Auditor for FY 2026-27, with over 15 years of experience.
Appointment of M/s Maya Sharma and Associates as Secretarial Auditor for a two-year term (FY 2025-26 and FY 2026-27).
Discontinuance of M/s M & Co. as the previous Secretarial Auditor effective August 1, 2026.

💡 No specific action is required as these are routine administrative appointments to ensure compliance with the Companies Act, 2013.

View All 530313 Announcements on Live Market Tracking →